EIP bags cash to trial ex-Vertex drug in dementia, Huntington's

EIP Pharma has raised $11.2 million to expand its clinical trial activities beyond Alzheimer's disease. The cash will fund midphase trials of an ex-Vertex drug in dementia and Huntington's disease.